| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Clinical Trial of the Intradermal TLR2 Agonist CADI-05 for BCG Recurrent and Unresponsive Non-Muscle Invasive Bladder Cancer
|
O’Donnell, Michael A.
|
|
2019
|
|
2 |
p. 171-180
|
article
|
| 2 |
Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy
|
Hamilton, Zach
|
|
2015
|
|
2 |
p. 137-142
|
article
|
| 3 |
A Management Algorithm for Mitomycin C Induced Cystitis
|
Luckenbaugh, Amy N.
|
|
2017
|
|
2 |
p. 133-138
|
article
|
| 4 |
A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy
|
Osawa, Takahiro
|
|
2016
|
|
2 |
p. 251-261
|
article
|
| 5 |
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation
|
Tan, Yiao
|
|
|
|
2 |
p. 165-177
|
article
|
| 6 |
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma
|
Knapp, Deborah W.
|
|
2016
|
|
2 |
p. 241-250
|
article
|
| 7 |
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma
|
Shimizu, Nobuaki
|
|
|
|
2 |
p. 179-192
|
article
|
| 8 |
Arsenic Induced Bladder Cancer
|
Messing, Edward M.
|
|
|
|
2 |
p. 223-224
|
article
|
| 9 |
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study
|
Ho, Chung-Han
|
|
|
|
2 |
p. 129-138
|
article
|
| 10 |
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy
|
Paré, Jean-Françcois
|
|
|
|
2 |
p. 175-186
|
article
|
| 11 |
Asymptomatic Microscopic Haematuria and Significant Urinary Tract Disease
|
Bryan, Richard T.
|
|
2019
|
|
2 |
p. 115-117
|
article
|
| 12 |
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection
|
Veskimae, Erik
|
|
|
|
2 |
p. 221-241
|
article
|
| 13 |
Author Index Volume 1 (2015)
|
|
|
2015
|
|
2 |
p. 189-190
|
article
|
| 14 |
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
|
Steinberg, Ryan L.
|
|
2015
|
|
2 |
p. 105-116
|
article
|
| 15 |
Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
|
Steinberg, Ryan L.
|
|
2016
|
|
2 |
p. 215-224
|
article
|
| 16 |
Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study
|
Schuettfort, Victor M.
|
|
|
|
2 |
p. 173-185
|
article
|
| 17 |
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy
|
Boström, Peter J.
|
|
2016
|
|
2 |
p. 263-272
|
article
|
| 18 |
Bladder Cancer Following Medicaid Expansion: No Changes in the Diagnosis of Muscle-Invasive Disease and Time to Treatment
|
Ko, Oliver S.
|
|
|
|
2 |
p. 143-150
|
article
|
| 19 |
Bladder Cancer Genetic Susceptibility. A Systematic Review
|
de Maturana, Evangelina López
|
|
2018
|
|
2 |
p. 215-226
|
article
|
| 20 |
Bladder Cancer Patient Advocacy: A Global Perspective
|
Quale, Diane Zipursky
|
|
2015
|
|
2 |
p. 117-122
|
article
|
| 21 |
Bladder Preservation for Muscle Invasive Bladder Cancer
|
Mirza, Arafat
|
|
2016
|
|
2 |
p. 151-163
|
article
|
| 22 |
CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis
|
Masson-Lecomte, Alexandra
|
|
2019
|
|
2 |
p. 159-169
|
article
|
| 23 |
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
|
Pan, Qi
|
|
2017
|
|
2 |
p. 79-88
|
article
|
| 24 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2018
|
|
2 |
p. 239-242
|
article
|
| 25 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2017
|
|
2 |
p. 139-140
|
article
|
| 26 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S.
|
|
2019
|
|
2 |
p. 181-183
|
article
|
| 27 |
Challenging Cases in Urothelial Cancer1
|
Soloway, Mark S.
|
|
|
|
2 |
p. 215-217
|
article
|
| 28 |
Challenging Cases in Urothelial Cancer: Case 20
|
Soloway, Mark S.
|
|
|
|
2 |
p. 253-255
|
article
|
| 29 |
Challenging Cases in Urothelial Cancer: Case 24
|
Soloway, Mark S.
|
|
|
|
2 |
p. 229-232
|
article
|
| 30 |
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome
|
Soloway, Mark S.
|
|
|
|
2 |
p. 193-199
|
article
|
| 31 |
Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
|
Ibrahim, Tony
|
|
2019
|
|
2 |
p. 87-102
|
article
|
| 32 |
Clinical Trials Corner
|
|
|
2016
|
|
2 |
p. 279-282
|
article
|
| 33 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
2017
|
|
2 |
p. 141-142
|
article
|
| 34 |
Clinical Trials Corner
|
|
|
2015
|
|
2 |
p. 181-183
|
article
|
| 35 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
2018
|
|
2 |
p. 243-244
|
article
|
| 36 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
2019
|
|
2 |
p. 185-187
|
article
|
| 37 |
Clinical Trials Corner
|
Agarwal, Piyush K.
|
|
|
|
2 |
p. 219-221
|
article
|
| 38 |
Clinical Trials Corner Issue 7(2)
|
Agarwal, Piyush K.
|
|
|
|
2 |
p. 257-260
|
article
|
| 39 |
Clinical Trials Corner Issue 8(2)
|
Agarwal, Piyush K.
|
|
|
|
2 |
p. 233-235
|
article
|
| 40 |
Clinical Trials Corner Issue 9(2)
|
Agarwal, Piyush K.
|
|
|
|
2 |
p. 187-190
|
article
|
| 41 |
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank
|
Kamat, Ashish M.
|
|
2016
|
|
2 |
p. 203-213
|
article
|
| 42 |
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer
|
Wessels, Frederik
|
|
|
|
2 |
p. 155-163
|
article
|
| 43 |
Considerations about Non-Metastatic Bladder Cancer Management During the COVID-19 Pandemic
|
Carvalho, Filipe L.F.
|
|
|
|
2 |
p. 99-106
|
article
|
| 44 |
Detection of Muscle-Invasive Bladder Cancer on Biparametric MRI Using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient Values (VI-RADS/ADC)
|
Sakamoto, Kazumasa
|
|
|
|
2 |
p. 161-169
|
article
|
| 45 |
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer
|
Jarow, Jonathan
|
|
2015
|
|
2 |
p. 133-136
|
article
|
| 46 |
Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference
|
Kaye, Deborah R.
|
|
2016
|
|
2 |
p. 225-234
|
article
|
| 47 |
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression
|
Godoy, Guilherme
|
|
2016
|
|
2 |
p. 127-137
|
article
|
| 48 |
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review
|
Lim, Amy H.
|
|
|
|
2 |
p. 193-209
|
article
|
| 49 |
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer
|
Melgarejo Segura, María Teresa
|
|
|
|
2 |
p. 159-166
|
article
|
| 50 |
Evaluation of Hematuria in a Large Public Health Care System
|
Ghandour, Rashed
|
|
2019
|
|
2 |
p. 119-129
|
article
|
| 51 |
Extraperitoneal Antegrade vs Transperitoneal Open Radical Cystectomy: Single Center Experiences with 200 Cases
|
Özkaptan, Orkunt
|
|
|
|
2 |
p. 187-194
|
article
|
| 52 |
Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer
|
Bastos, Diogo A.
|
|
|
|
2 |
p. 171-186
|
article
|
| 53 |
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol
|
Diana, Pietro
|
|
|
|
2 |
p. 119-127
|
article
|
| 54 |
Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications
|
Alderson, Meera
|
|
|
|
2 |
p. 107-122
|
article
|
| 55 |
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer
|
Moore, Assaf
|
|
|
|
2 |
p. 141-150
|
article
|
| 56 |
Id Proteins Contribute to Tumor Development and MetastaticColonization in a Model of Bladder Carcinogenesis
|
Garcia-Cao, Marta
|
|
2015
|
|
2 |
p. 159-170
|
article
|
| 57 |
Implementing a New Standard of Care
|
Messing, Edward M.
|
|
|
|
2 |
p. 237-239
|
article
|
| 58 |
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival
|
Kimura, Takahiro
|
|
|
|
2 |
p. 205-211
|
article
|
| 59 |
In the World of Bladder Tumors: Size Does Matter
|
Loloi, Justin
|
|
|
|
2 |
p. 195-200
|
article
|
| 60 |
Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma
|
van Hoogstraten, Lisa M.C.
|
|
|
|
2 |
p. 193-203
|
article
|
| 61 |
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1
|
Tu, Megan M.
|
|
|
|
2 |
p. 131-145
|
article
|
| 62 |
MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation
|
Walker, Alexandra K.
|
|
2019
|
|
2 |
p. 147-157
|
article
|
| 63 |
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
|
Sommer, Breann C.
|
|
2018
|
|
2 |
p. 149-159
|
article
|
| 64 |
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer
|
Messing, Edward M.
|
|
|
|
2 |
p. 191-192
|
article
|
| 65 |
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences
|
Tazeh, Ngii N.
|
|
2017
|
|
2 |
p. 89-94
|
article
|
| 66 |
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors
|
Wang, Yuanshuo A.
|
|
|
|
2 |
p. 125-139
|
article
|
| 67 |
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
|
Yang, Alexander
|
|
|
|
2 |
p. 211-213
|
article
|
| 68 |
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer
|
Zhang, JJ H.
|
|
|
|
2 |
p. 109-123
|
article
|
| 69 |
Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients
|
Patel, Sanjay
|
|
2015
|
|
2 |
p. 143-150
|
article
|
| 70 |
Paper Alert
|
Messing, Edward M.
|
|
2015
|
|
2 |
p. 185-187
|
article
|
| 71 |
Paper Alert
|
Messing, Edward M.
|
|
2016
|
|
2 |
p. 283-284
|
article
|
| 72 |
Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives
|
Kita, Yuki
|
|
|
|
2 |
p. 131-141
|
article
|
| 73 |
Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
|
Bachir, Bassel G.
|
|
2017
|
|
2 |
p. 105-112
|
article
|
| 74 |
“Picture this”- Patients’ Drawings of Non-Muscle Invasive Bladder Cancer: A Novel Method to Help Understand How Patients Perceive Their Condition
|
Richards, Helen L.
|
|
|
|
2 |
p. 149-159
|
article
|
| 75 |
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
|
Alam, Syed M.
|
|
|
|
2 |
p. 167-174
|
article
|
| 76 |
Preoperative Risk Factors Predicting Postoperative Complications in Radical Cystectomy for Bladder Cancer
|
Niu, Sida
|
|
|
|
2 |
p. 151-159
|
article
|
| 77 |
Preventing Bladder Recurrences after Nephroureterectomy for Upper Track Urothelial Cancer
|
Messing, Edward M.
|
|
2019
|
|
2 |
p. 189-191
|
article
|
| 78 |
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants
|
Ku, Ja Hyeon
|
|
2018
|
|
2 |
p. 195-203
|
article
|
| 79 |
Psychological Stress and Suicide in Bladder Cancer Patients
|
Messing, Edward M.
|
|
2018
|
|
2 |
p. 245-246
|
article
|
| 80 |
Pursuing Quality in the Application of Bladder Cancer Quality of Life Research
|
Mohamed, N.E.
|
|
2016
|
|
2 |
p. 139-149
|
article
|
| 81 |
Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection
|
Noval Rivas, Magali
|
|
|
|
2 |
p. 121-131
|
article
|
| 82 |
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
|
Galsky, Matthew D.
|
|
2018
|
|
2 |
p. 227-238
|
article
|
| 83 |
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
|
Kamat, Ashish M.
|
|
|
|
2 |
p. 113-117
|
article
|
| 84 |
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
|
Boxley, Peter
|
|
|
|
2 |
p. 123-129
|
article
|
| 85 |
Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate
|
Kokorovic, Andrea
|
|
|
|
2 |
p. 243-252
|
article
|
| 86 |
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer
|
Meghani, Khyati
|
|
|
|
2 |
p. 101-112
|
article
|
| 87 |
Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial
|
Enikeev, Dmitry
|
|
|
|
2 |
p. 201-210
|
article
|
| 88 |
Significance and Mechanisms Analyses of RB1 Mutation in Bladder Cancer Disease Progression and Drug Selection by Bioinformatics Analysis
|
Zhang, Dingguo
|
|
|
|
2 |
p. 133-142
|
article
|
| 89 |
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)
|
Dalbagni, Guido
|
|
2017
|
|
2 |
p. 113-119
|
article
|
| 90 |
Single Instillation of Hypertonic Saline Immediately Following Transurethral Resection of Bladder Tumor for Recurrence Prevention –A Phase I Study
|
Modai, Jonathan
|
|
|
|
2 |
p. 187-192
|
article
|
| 91 |
Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma
|
Grivas, Petros
|
|
|
|
2 |
p. 143-148
|
article
|
| 92 |
Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
|
Lerner, Seth P.
|
|
2016
|
|
2 |
p. 165-202
|
article
|
| 93 |
Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
|
Patel, Vaibhav
|
|
2017
|
|
2 |
p. 121-132
|
article
|
| 94 |
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines
|
Zuiverloon, Tahlita C.M.
|
|
2018
|
|
2 |
p. 169-183
|
article
|
| 95 |
Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra
|
Patschan, Oliver
|
|
|
|
2 |
p. 213-220
|
article
|
| 96 |
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy
|
Rola, Jenna
|
|
|
|
2 |
p. 151-157
|
article
|
| 97 |
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis
|
van Hattum, Jons W.
|
|
|
|
2 |
p. 211-228
|
article
|
| 98 |
The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis
|
Kamat, Ashish M.
|
|
2016
|
|
2 |
p. 273-278
|
article
|
| 99 |
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands
|
van Hoogstraten, Lisa M.C.
|
|
|
|
2 |
p. 139-154
|
article
|
| 100 |
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study
|
Kaiser, Jeenan
|
|
2018
|
|
2 |
p. 185-194
|
article
|
| 101 |
The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients
|
Krughoff, Kevin
|
|
2015
|
|
2 |
p. 171-179
|
article
|
| 102 |
The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer
|
Lewis, Gary D.
|
|
2018
|
|
2 |
p. 205-213
|
article
|
| 103 |
The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy
|
Puttmann, Kathleen
|
|
2019
|
|
2 |
p. 103-114
|
article
|
| 104 |
The Role of Population-Based Observational Research in Bladder Cancer
|
Robinson, Andrew G.
|
|
2015
|
|
2 |
p. 123-131
|
article
|
| 105 |
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study
|
Jahnson, Staffan
|
|
|
|
2 |
p. 161-171
|
article
|
| 106 |
Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention
|
Zareba, Piotr
|
|
2018
|
|
2 |
p. 139-147
|
article
|
| 107 |
Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy
|
Matulewicz, Richard S.
|
|
2018
|
|
2 |
p. 161-167
|
article
|
| 108 |
Treatment Decision Making in Patients with Bladder Cancer
|
Berry, Donna L.
|
|
2015
|
|
2 |
p. 151-158
|
article
|
| 109 |
Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy
|
Luckenbaugh, Amy N.
|
|
2016
|
|
2 |
p. 235-240
|
article
|
| 110 |
WBC Associates with Readmission Following Cystectomy
|
McIntosh, Andrew G.
|
|
2017
|
|
2 |
p. 95-103
|
article
|
Journal description